262 related articles for article (PubMed ID: 34990594)
1. Screening approaches and therapeutic targets: The two driving wheels of tuberculosis drug discovery.
Perveen S; Sharma R
Biochem Pharmacol; 2022 Mar; 197():114906. PubMed ID: 34990594
[TBL] [Abstract][Full Text] [Related]
2. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
de Wet TJ; Warner DF; Mizrahi V
Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
[TBL] [Abstract][Full Text] [Related]
3. Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.
Manjunatha UH; Smith PW
Bioorg Med Chem; 2015 Aug; 23(16):5087-97. PubMed ID: 25577708
[TBL] [Abstract][Full Text] [Related]
4. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
5. Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead.
Grotz E; Tateosian N; Amiano N; Cagel M; Bernabeu E; Chiappetta DA; Moretton MA
Pharm Res; 2018 Sep; 35(11):213. PubMed ID: 30238168
[TBL] [Abstract][Full Text] [Related]
6. Strategies to Combat Multi-Drug Resistance in Tuberculosis.
Singh V; Chibale K
Acc Chem Res; 2021 May; 54(10):2361-2376. PubMed ID: 33886255
[TBL] [Abstract][Full Text] [Related]
7. Strategies in anti-Mycobacterium tuberculosis drug discovery based on phenotypic screening.
Grzelak EM; Choules MP; Gao W; Cai G; Wan B; Wang Y; McAlpine JB; Cheng J; Jin Y; Lee H; Suh JW; Pauli GF; Franzblau SG; Jaki BU; Cho S
J Antibiot (Tokyo); 2019 Oct; 72(10):719-728. PubMed ID: 31292530
[TBL] [Abstract][Full Text] [Related]
8. The tuberculosis drug discovery and development pipeline and emerging drug targets.
Mdluli K; Kaneko T; Upton A
Cold Spring Harb Perspect Med; 2015 Jan; 5(6):. PubMed ID: 25635061
[TBL] [Abstract][Full Text] [Related]
9. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
10. The Expanding Diversity of Mycobacterium tuberculosis Drug Targets.
Wellington S; Hung DT
ACS Infect Dis; 2018 May; 4(5):696-714. PubMed ID: 29412643
[TBL] [Abstract][Full Text] [Related]
11. A high-throughput target-based screening approach for the identification and assessment of
Smiejkowska N; Oorts L; Van Calster K; De Vooght L; Geens R; Mattelaer H-P; Augustyns K; Strelkov SV; Lamprecht D; Temmerman K; Sterckx YG-J; Cappoen D; Cos P
Microbiol Spectr; 2024 Mar; 12(3):e0372323. PubMed ID: 38315026
[TBL] [Abstract][Full Text] [Related]
12. Tuberculosis drug discovery in the CRISPR era.
Rock J
PLoS Pathog; 2019 Sep; 15(9):e1007975. PubMed ID: 31536613
[TBL] [Abstract][Full Text] [Related]
13. Development of Mycobacterium tuberculosis whole cell screening hits as potential antituberculosis agents.
Cooper CB
J Med Chem; 2013 Oct; 56(20):7755-60. PubMed ID: 23927683
[TBL] [Abstract][Full Text] [Related]
14. Key targets and relevant inhibitors for the drug discovery of tuberculosis.
Xiong X; Xu Z; Yang Z; Liu Y; Wang D; Dong M; Parker EJ; Zhu W
Curr Drug Targets; 2013 Jun; 14(6):676-99. PubMed ID: 23547780
[TBL] [Abstract][Full Text] [Related]
15. The future for early-stage tuberculosis drug discovery.
Zuniga ES; Early J; Parish T
Future Microbiol; 2015; 10(2):217-29. PubMed ID: 25689534
[TBL] [Abstract][Full Text] [Related]
16. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
Kiran D; Podell BK; Chambers M; Basaraba RJ
Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
[TBL] [Abstract][Full Text] [Related]
17. Target Discovery for New Antitubercular Drugs Using a Large Dataset of Growth Inhibitors from PubChem.
Goldman RC
Infect Disord Drug Targets; 2020; 20(3):352-366. PubMed ID: 30520384
[TBL] [Abstract][Full Text] [Related]
18. Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promises on the horizon.
Bhat ZS; Rather MA; Maqbool M; Ahmad Z
Biomed Pharmacother; 2018 Jul; 103():1733-1747. PubMed ID: 29864964
[TBL] [Abstract][Full Text] [Related]
19. Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis - a critical review.
Singh J; Garg T; Rath G; Goyal AK
Drug Deliv; 2016 Jun; 23(5):1676-98. PubMed ID: 26289212
[TBL] [Abstract][Full Text] [Related]
20. The quest for the holy grail: new antitubercular chemical entities, targets and strategies.
Huszár S; Chibale K; Singh V
Drug Discov Today; 2020 Apr; 25(4):772-780. PubMed ID: 32062007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
